Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it

Research output: Contribution to journalEditorial

7 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)298-300
Number of pages3
JournalAnnals of Oncology
Volume29
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Centers for Medicare and Medicaid Services (U.S.)
Medicine

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{65973adebbdd4622a0cc55aebf4046e7,
title = "Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it",
author = "Vinay Prasad",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/annonc/mdx786",
language = "English (US)",
volume = "29",
pages = "298--300",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it

AU - Prasad, Vinay

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://www.scopus.com/inward/record.url?scp=85042564314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042564314&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx786

DO - 10.1093/annonc/mdx786

M3 - Editorial

VL - 29

SP - 298

EP - 300

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -